Defining Optic Nerve Tortuosity

References

1. ↵
   Littler M, Morton NE. Segregation analysis of peripheral neurofibromatosis (NF1). J Med Genet 1990;27:307–10

   Abstract/FREE Full Text
2. ↵
   Anonymous. Neurofibromatosis. Conference statement. National Institutes of Health Consensus development conference. Arch Neurol 1988;45:575–78

   CrossRefPubMedWeb of Science
3. ↵
   Lewis RA, Gerson LP, Axelson KA, et al. von Recklinghausen neurofibromatosis. II. Incidence of optic gliomata. Ophthalmology 1984;91:929–35

   CrossRefPubMedWeb of Science
4. Listernick R, Charrow J, Greenwald M, et al. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr 1994;125:63–66

   CrossRefPubMedWeb of Science
5. ↵
   Listernick R, Charrow J, Greenwald MJ, et al. Optic gliomas in children with neurofibromatosis type 1. J Pediatr 1989;114:788–92

   CrossRefPubMed
6. ↵
   Balcer LJ, Liu GT, Heller G, et al. Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging. Am J Ophthalmol 2001;131:442–45

   CrossRefPubMedWeb of Science
7. ↵
   Aoki S, Barkovich AJ, Nishimura K, et al. Neurofibromatosis types 1 and 2: cranial MR findings. Radiology 1989;172:527–34

   PubMedWeb of Science
8. Curless RG, Siatkowski M, Glaser JS, et al. MRI diagnosis of NF-1 in children without cafe-au-lait skin lesions. Pediatr Neurol 1998;18:269–71

   CrossRefPubMedWeb of Science
9. Menor F, Marti-Bonmati L, Arana E, et al. Neurofibromatosis type 1 in children: MR imaging and follow-up studies of central nervous system findings. Eur J Radiol 1998;26:121–31

   CrossRefPubMed
10. ↵
    Raininko R, Thelin L, Eeg-Olofsson O. Non-neoplastic brain abnormalities on MRI in children and adolescents with neurofibromatosis type 1. Neuropediatrics 2001;32:225–30

    CrossRefPubMed
11. ↵
    DiMario FJ Jr, Ramsby G, Greenstein R, et al. Neurofibromatosis type 1: magnetic resonance imaging findings. J Child Neurol 1993;8:32–39

    Abstract/FREE Full Text
12. ↵
    Farrar JT, Portenoy RK, Berlin JA, et al. Defining the clinically important difference in pain outcome measures. Pain 2000;88:287–94

    CrossRefPubMedWeb of Science
13. ↵
    Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149–58

    CrossRefPubMedWeb of Science
14. ↵
    Streiner DL, Norman GR. Scaling responses. In: Health Measurement Scales: A Practical Guide to Their Development and Use. 3rd ed. Oxford: Oxford University Press;2003 :29–60
15. ↵
    Streiner DL, Norman GR. Basic concepts. In: Health Measurement Scales: A Practical Guide to Their Development and Use. 3rd ed. Oxford: Oxford University Press;2003 :4–13
16. ↵
    Rosner B. Probability. In: Rosner B, ed. Fundamentals of Biostatistics, 5th ed. Pacific Grove, Calif: Duxbury Thompson Learning;2000 :45–78
17. ↵
    Sackett DL, Haynes RB, Guyatt GH, et al. Clinical Epidemiology: A Basic Science for Clinical Medicine, 2nd ed. Boston: Little, Brown and Company;1991 :128–29
18. ↵
    Fink A, Kosecoff J, Chassin M, et al. Consensus methods: characteristics and guidelines for use. Am J Public Health 1984;74:979–83

    CrossRefPubMedWeb of Science
19. ↵
    Holmes GP, Kaplan JE, Gantz NM, et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988;108:387–89

    CrossRefPubMedWeb of Science
20. ↵
    Todd KH, Funk JP. The minimum clinically important difference in physician-assigned visual analog pain scores. Acad Emerg Med 1996;3:142–46

    CrossRefPubMedWeb of Science